Holcim Ltd Unsponsored ADR (OTCMKTS:HCMLY – Get Free Report) has been given a consensus recommendation of “Buy” by the eight research firms that are currently covering the stock, Marketbeat reports. Two research analysts have rated the stock with a hold rating, four have assigned a buy rating and two have assigned a strong buy rating to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $16.80.
Several equities research analysts recently weighed in on the company. Royal Bank Of Canada restated a “sector perform” rating on shares of Holcim in a report on Monday. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Holcim in a report on Friday, July 3rd.
Check Out Our Latest Stock Report on HCMLY
Holcim Stock Down 0.3%
Shares of HCMLY traded down $0.05 during trading hours on Monday, hitting $16.07. 234,421 shares of the company were exchanged, compared to its average volume of 156,891. The company has a debt-to-equity ratio of 0.51, a quick ratio of 0.84 and a current ratio of 1.09. The firm’s 50 day moving average is $16.58 and its 200-day moving average is $17.79. Holcim has a 52 week low of $14.79 and a 52 week high of $21.23.
Holcim Company Profile
Holcim Ltd. is a Switzerland-based global building materials and solutions company. Its products and services support residential, commercial and infrastructure construction, with operations spanning cement, aggregates, ready-mix concrete and related building solutions.
The company also provides value-added products such as roofing systems, insulation, facade solutions and other materials designed to improve the performance, durability and sustainability of buildings. Holcim serves customers including construction companies, contractors, developers, distributors and infrastructure operators.
Holcim traces its history to Switzerland and expanded significantly through international growth and acquisitions.
Featured Stories
- Five stocks we like better than Holcim
- Comfort Systems Earnings: AI Slowdown or More Growth Ahead?
- Bristol Myers Squibb’s Cancer Breakthrough Could Have Implications Beyond Its Own Stock
- 5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps
- Anthropic’s IPO Filing Reveals a Massive Opportunity for AI Infrastructure Giants
Receive News & Ratings for Holcim Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Holcim and related companies with MarketBeat.com's FREE daily email newsletter.
